Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2000
11/14/2000US6146831 Cellular models for diabetes and other diseases associated with mitochondrial defects
11/14/2000US6146643 A hepatitis a virus having a genome consisting of a human attenuated hepatitis a virus sequence wherein the 5' noncoding region has been replaced by the 5' noncoding region of simian hepatitis a virus agm-27
11/14/2000US6146642 Recombinant new castle disease virus RNA expression systems and vaccines
11/14/2000US6146641 Avian leukosis virus subgroup J envelope gene product for diagnosis and immunogenic composition
11/14/2000US6146635 System for the expression of heterologous antigens as fusion proteins
11/14/2000US6146634 Proteins with urease activity
11/14/2000US6146633 Endogenous and exogenous proteins, and fragments are chemically modified outside the body of an animal so that when injected into the animal, they produce more antibodies against the unmodified protein unmodified protein alone
11/14/2000US6146632 Vaccines
11/14/2000US6146630 Inhibitors for the adhesion of lymphocytes to glandular cells
11/14/2000CA1341140C Structural phosphoprotein (pp28) of human cytomegalovirus (hcmv), the preparation and use thereof
11/10/2000CA2307446A1 Complex for transferring an anionic substance of interest into a cell
11/09/2000WO2000066791A1 Neisseria genomic sequences and methods of their use
11/09/2000WO2000066741A2 Conserved neisserial antigens
11/09/2000WO2000066739A2 Chlamydia antigens and corresponding dna fragments and uses thereof
11/09/2000WO2000066735A2 Human ion channel proteins
11/09/2000WO2000066727A1 Tumour-associated antigen
11/09/2000WO2000066722A1 Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof
11/09/2000WO2000066715A1 Method for diminishing specific immune reactions
11/09/2000WO2000066710A2 Method for the preservation of viruses and mycoplasma
11/09/2000WO2000066708A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
11/09/2000WO2000066631A1 SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?
11/09/2000WO2000066624A1 Helicobacter pylori antigens
11/09/2000WO2000066621A1 Peptides from the tt virus sequence and monospecific antibodies binding to the tt virus
11/09/2000WO2000066182A1 X-ray guided drug delivery
11/09/2000WO2000066179A1 Noninvasive genetic immunization, expression products therefrom, and uses thereof
11/09/2000WO2000066178A1 Lim mineralization protein splice variants
11/09/2000WO2000066162A1 Mutant human cd80 and compositions for and methods of making and using the same
11/09/2000WO2000066160A1 Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
11/09/2000WO2000066159A1 Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
11/09/2000WO2000066157A1 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
11/09/2000WO2000066156A1 Death domain containing receptor 5
11/09/2000WO2000066155A1 Methods for preventing reactivation of latent virus and controlling virus replication
11/09/2000WO2000066154A2 Anti-microbial agents, diagnostic reagents, and vaccines based on unique apicomplexan parasite components
11/09/2000WO2000066153A1 RAS ONCOGEN p21 PEPTIDE VACCINES
11/09/2000WO2000066151A1 Use of heparin-binding antagonists in the inhibition of bradykinin release
11/09/2000WO2000066143A1 Secreted proteins of mycobacterium tuberculosis and their use as vaccines and diagnostic reagents
11/09/2000WO2000066141A2 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
11/09/2000WO2000066090A1 Amplification of folate-mediated targeting to tumor cells using nanoparticles
11/09/2000WO2000041720A8 Improved saponin adjuvant compositions and methods relating thereto
11/09/2000WO2000041463A3 Combination of hepatitis b vaccine with antiviral agents
11/09/2000WO2000038718A3 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia
11/09/2000WO2000038710A3 Dual hapten modified tumor cells and tumor polypeptides and methods of treating cancer
11/09/2000WO2000037105A3 Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
11/09/2000WO2000036091A3 An animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
11/09/2000WO2000034497A3 Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
11/09/2000WO2000034447A3 Human ubiquitin ligase e3 for the modulation of nf-kappa b
11/09/2000WO2000032794A3 Chlamydia antigens and corresponding dna fragments and uses thereof
11/09/2000WO2000032226A3 Xenograft animal model for the induction of papillomas, the production of papillomavirus and the propagation thereof
11/09/2000WO2000030668A3 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
11/09/2000WO2000029428A3 5t4 tumour-associated antigen for use in tumour immunotherapy
11/09/2000WO2000024771A3 Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
11/09/2000WO2000024765A3 Chlamydia antigens and corresponding dna fragments and uses thereof
11/09/2000WO2000021996A3 Methods and compositions for inhibiting neoplastic cell growth
11/09/2000WO2000020638A3 Methods and compositions for the diagnosis and therapy of prostate cancer
11/09/2000WO2000018929A3 Paramyxovirus vaccines
11/09/2000WO2000015826A3 Leptin induced genes
11/09/2000WO2000014112A3 Papillomaviruses, means for the detection thereof and therapy for diseases caused thereby
11/09/2000WO2000006737A8 Streptococcus pneumoniae proteins and nucleic acid molecules
11/09/2000WO1999055868A3 Fizz proteins
11/09/2000CA2377131A1 Anti-microbial agents, diagnostic reagents, and vaccines based on unique apicomplexan parasite components
11/09/2000CA2373021A1 Chlamydia antigens and corresponding dna fragments and uses thereof
11/09/2000CA2372834A1 Amplification of folate-mediated targeting to tumor cells using nanoparticles
11/09/2000CA2372235A1 Conserved neisserial antigens
11/09/2000CA2372192A1 Lim mineralization protein splice variants
11/09/2000CA2372187A1 Ras oncogen p21 peptide vaccines
11/09/2000CA2371766A1 Noninvasive genetic immunization, expression products therefrom, and uses thereof
11/09/2000CA2371596A1 Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof
11/09/2000CA2371427A1 Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
11/09/2000CA2371421A1 Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
11/09/2000CA2371032A1 Neisseria genomic sequences and methods of their use
11/09/2000CA2370821A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
11/09/2000CA2370587A1 Use of heparin-binding antagonists in the inhibition of bradykinin release
11/09/2000CA2370495A1 Peptides from the tt virus sequence and monospecific antibodies binding to the tt virus
11/09/2000CA2370304A1 Specific antibodies and antibody fragments for tgf.beta.1
11/09/2000CA2369747A1 Mutant human cd80 and compositions for and methods of making and using the same
11/09/2000CA2369371A1 Death domain containing receptor 5
11/09/2000CA2368748A1 X-ray guided drug delivery
11/09/2000CA2365900A1 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
11/09/2000CA2365776A1 Method for treating abnormal cell proliferation in the brain
11/09/2000CA2365440A1 Human ion channel proteins
11/09/2000CA2365278A1 Tumour-associated antigen
11/09/2000CA2365277A1 Method for the preservation of viruses and mycoplasma
11/08/2000EP1050541A1 Babesia vaccine
11/08/2000EP1050307A1 CCR4 antagonists in sepsis
11/08/2000EP1049788A2 Protein expression in baculovirus vector expression systems
11/08/2000EP1049787A1 Multipurpose antibody derivatives
11/08/2000EP1049781A1 Human chemokine and its use for detection and treatment of breast disease
11/08/2000EP1049759A1 Novel polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
11/08/2000EP1049718A1 Monoclonal antibody anti alphav-integrin and its use to inhibit alphavbeta6-integrin attachment to fibronectin
11/08/2000EP1049717A2 Antibodies against human il-12
11/08/2000EP1049711A1 Liposomes comprising peptide antigens derived from x protein of hepatitis b virus
11/08/2000EP1049490A2 Method for inhibiting cd95-independent apoptosis in aids
11/08/2000EP1049489A1 Agent capable of modulating a glycosphingolipid-associated activity thus affecting an immune disorder
11/08/2000EP1049488A1 METHOD OF AND COMPOSITIONS FOR IMMUNIZATION WITH THE $i(PSEUDOMONAS) V ANTIGEN
11/08/2000EP1049483A1 Method for treating inflammatory diseases using heat shock proteins
11/08/2000EP1049477A1 Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
11/08/2000EP0687180B1 Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/tyrosinase peptide antigens
11/08/2000EP0636029B1 Antibodies specific for carcinoma-associated antigens
11/08/2000EP0635132B1 Broadly reactive opsonic antibodies that react with common staphylococcal antigens
11/08/2000CN1272886A Polynucleotide encoding polypeptide having heparanase activity and expression of same in transduced cells
1 ... 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 ... 1823